2022 - Research.com Medicine in Ireland Leader Award
His main research concerns Cancer, Breast cancer, Internal medicine, Oncology and Cancer research. His work deals with themes such as Malignancy, Immunology and Metalloproteinase, which intersect with Cancer. The concepts of his Breast cancer study are interwoven with issues in Serine protease, Plasminogen activator inhibitor-1 and Pathology.
In his study, which falls under the umbrella issue of Internal medicine, Stomach cancer is strongly linked to Gastroenterology. His Oncology study combines topics from a wide range of disciplines, such as CA 15-3, Carcinoembryonic antigen, Trastuzumab, Ovarian cancer and Disease. His Cancer research research includes themes of Plasminogen activator, Extracellular matrix, Matrix metalloproteinase and Survivin.
Internal medicine, Breast cancer, Cancer, Cancer research and Oncology are his primary areas of study. The study incorporates disciplines such as Gastroenterology and Endocrinology in addition to Internal medicine. His Breast cancer study incorporates themes from Immunology and Pathology.
His study in Cancer is interdisciplinary in nature, drawing from both Malignancy and Matrix metalloproteinase. His studies examine the connections between Cancer research and genetics, as well as such issues in Plasminogen activator, with regards to Urokinase and Tissue plasminogen activator. Michael J. Duffy interconnects Carcinoembryonic antigen, Trastuzumab, Ovarian cancer, CA15-3 and Biomarker in the investigation of issues within Oncology.
Michael J. Duffy mainly investigates Breast cancer, Internal medicine, Oncology, Cancer research and Cancer. The Breast cancer study combines topics in areas such as Targeted therapy, Metastasis and Immunology. Michael J. Duffy focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Endocrinology and, in certain cases, Cancer cell and Androgen receptor.
His Oncology research is multidisciplinary, incorporating perspectives in Biomarker, Ovarian cancer, Disease and Asymptomatic. His work carried out in the field of Cancer research brings together such families of science as Cell culture, Cell growth, Apoptosis and Mutant, Gene. His Cancer research is multidisciplinary, relying on both Malignancy, Clinical trial and Pathology.
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His study in the fields of Plasminogen activator inhibitor-1, Immunohistochemistry and Trastuzumab under the domain of Internal medicine overlaps with other disciplines such as In patient and Microsatellite instability. His Breast cancer study integrates concerns from other disciplines, such as Receptor, Targeted therapy and Immunology.
His Oncology research incorporates elements of Biomarker, Ovarian cancer, CA15-3 and Pertuzumab. His work in Cancer covers topics such as Pathology which are related to areas like Metastasis and Tumor Biomarkers. His Cancer research research is multidisciplinary, incorporating elements of Cell culture, Cell, Mutant and Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR SYSTEM IN CANCER METASTASIS: A REVIEW
Peter A. Andreasen;Lars Kjøller;Lise Christensen;Michael J. Duffy.
International Journal of Cancer (1997)
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Michael J. Duffy.
Clinical Chemistry (2001)
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.
Michael J Duffy;Teresa M Maguire;Arnold Dk Hill;Enda McDermott.
Breast Cancer Research (2000)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
M.J. Duffy;A. van Dalen;C. Haglund;L. Hansson.
European Journal of Cancer (2007)
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Michael J. Duffy.
Clinical Chemistry (2006)
Survivin: A new target for anti-cancer therapy
Bríd M. Ryan;Norma O’Donovan;Michael J. Duffy.
Cancer Treatment Reviews (2009)
The urokinase plasminogen activator system: role in malignancy.
Michael J Duffy.
Current Pharmaceutical Design (2004)
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
M.J Duffy;A van Dalen;C Haglund;L Hansson.
European Journal of Cancer (2003)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon;Michael J. Duffy;Ulf Håkan Stenman;Hans Lilja.
Clinical Chemistry (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: